Effect of S-1 in a patient with metastatic eyelid sebaceous carcinoma

Satsuki Yasumura*, Hideo Shojaku, Hiromasa Takakura, Michiro Fujisaka, Masahito Tsubota, Akira Naruse, Hirohiko Tachino, Motoyoshi Maruyama, Yukio Watanabe

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We report a 68-year-old female with a history of repeated right cervical lymph node metastasis secondary to eyelid sebaceous carcinoma. She had undergone right neck dissection due to lymph node metastasis at the department of surgery in an other local hospital. After the orbital exenteration, she underwent multiple operations, including 2 right partial parotidectomy and then total parotidectomy, 4 right cervical lymph node excisions and 1 left upper neck dissection due to lymph node metastasis. Adjuvant chemotherapy with S-1 (at a dose of 80 mg per day) alone was applied as tumor dormancy therapy on an outpatient basis. Any adverse events during S-1 medication were observed. New metastatic lesions were not found until 29 months after the beginning of chemotherapy with S-1 alone. Although the effectiveness of S-1 for eyelid sebaceous carcinoma has not been demonstrated, S-1 might be useful in patients with recurrent eyelid sebaceous carcinoma based on our patient's recurrence-free survival.

Original languageEnglish
Pages (from-to)983-986
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume38
Issue number6
StatePublished - 2011/06

Keywords

  • Long-term
  • Recurrence-free survival
  • S-1
  • Sebaceous carcinoma of eyelid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Effect of S-1 in a patient with metastatic eyelid sebaceous carcinoma'. Together they form a unique fingerprint.

Cite this